A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. [electronic resource]
Producer: 20180305Description: 697-706 p. digitalISSN:- 1557-3265
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Benzimidazoles -- administration & dosage
- DNA Methylation -- drug effects
- DNA Modification Methylases -- genetics
- DNA Repair Enzymes -- genetics
- Dacarbazine -- administration & dosage
- Drug Synergism
- Esophagitis -- chemically induced
- Female
- Histones -- metabolism
- Humans
- Kaplan-Meier Estimate
- Leukemia, Myeloid, Acute -- drug therapy
- Leukemia, Myelomonocytic, Chronic -- drug therapy
- Male
- Middle Aged
- Mucositis -- chemically induced
- Neoplasm Proteins -- analysis
- Phosphorylation -- drug effects
- Poly (ADP-Ribose) Polymerase-1 -- analysis
- Poly(ADP-ribose) Polymerase Inhibitors -- administration & dosage
- Promoter Regions, Genetic -- drug effects
- Protein Processing, Post-Translational -- drug effects
- Remission Induction
- Salvage Therapy
- Temozolomide
- Tumor Suppressor Proteins -- genetics
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article
There are no comments on this title.
Log in to your account to post a comment.